Biotechnology companies can use “value-chain analysis” to create processes for maximizing the value of their intellectual property portfolios, say Bill Barrett and Dave Crawford. Every ...

"This is driving the evolution of pharmaceutical value chain and providing space for firms from countries such as India and China to become key nodal points." Analysis of MNCs and companies from ...